<DOC>
	<DOC>NCT02712905</DOC>
	<brief_summary>This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 2 parts. Part 1 (dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and/or a tolerated pharmacologically active dose. Part 2 (dose expansion) will further determine the safety, tolerability, efficacy, PK, and PD of the selected dose(s).</brief_summary>
	<brief_title>An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Male or female subjects, age 18 years or older. Presence of measurable disease that has been confirmed by histology or cytology. Must not be a candidate for potentially curative therapy or standardofcare approved therapy Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. Receipt of anticancer medications, anticancer therapies, or investigational drugs within the defined interval before the first administration of study drug. Any unresolved toxicity ≥ Grade 2 from previous anticancer therapy except for stable chronic toxicities (≤ Grade 2) not expected to resolve. Laboratory and medical history parameters outside Protocoldefined range. Known additional malignancy that is progressing or requires active treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute myeloid leukemia (AML)</keyword>
	<keyword>myelodysplastic syndrome (MDS)</keyword>
	<keyword>small cell lung cancer (SCLC)</keyword>
	<keyword>myelofibrosis (MF)</keyword>
	<keyword>solid tumor, lysine-specific demethylase 1 (LSD1) inhibitor</keyword>
</DOC>